Noxopharm (ASX:NOX) is an innovative Australian biotech company that is researching and developing treatments for cancer and inflammation.
Their lead clinical-stage drug candidate, Veyonda®, is being tested in their DARRT-2 clinical trial for its efficacy in combination with low-dose external beam radiotherapy for the treatment of prostate cancer.
The Safety Steering Committee has reviewed safety data from the third cohort of patients, and the 1600mg dose was found to be safe.
The trial is set to progress into Part 2, which will evaluate efficacy signals while safety data is collected, in late Q1 or early Q2 of 2023.
Noxopharm is also actively exploring ways to reduce patient numbers and costs while bringing forward efficacy data.
They are aiming to release results via high-profile conferences and peer-reviewed publications to maximise commercial potential.